QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.092262v1 316/2/581    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Madjid, N. Articles by Ögren, S. O. Search for Related Content PubMed PubMed Citation Articles by Madjid, N. Articles by Ögren, S. O. Pubmed/NCBI databases Substance via MeSH

NEUROPHARMACOLOGY

5-Hydroxytryptamine 1A Receptor Blockade Facilitates Aversive Learning in Mice: Interactions with Cholinergic and Glutamatergic Mechanisms

Department of Neuroscience, Division of Behavioral Neuroscience, Karolinska Institutet, Stockholm, Sweden (N.M., E.E.T., M.L., B.M., J.S., A.K., S.O.Ö.); Department of Clinical Neuroscience, Karolinska University Hospital, Stockholm, Sweden (M.L.); and Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Free University, Amsterdam, The Netherlands (O.S.)

The effects of 5-hydroxytryptamine 1A (5-HT_1A) receptor ligands on aversive learning were examined in the passive avoidance (PA) task in mice. Anxiety and autonomic functions were investigated using the elevated plus-maze and heart rate measurements. The main findings from this study are as follows. 1) Pretraining administration of the 5-HT_1A receptor agonist 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide] facilitated PA retention at low doses (0.01 and 0.03 mg/kg) but impaired PA retention at higher doses (0.1-1.0 mg/kg), consistent with previous findings in the rat. 2) Similar to the acetylcholinesterase inhibitor physostigmine, pretraining administration of the 5-HT_1A receptor antagonists [(R)-3-N,N-dicyclobutylamino-8 fluoro-3,4-dihydro-3H-1-benzopyran-5-carboxamide hydrogen(2R,3R)-tartrate monohydrate] NAD-299 (0.1-2 mg/kg) and [N-2-4-(2-methoxyphenyl)-1-piperazinylethyl-N-(2-pyridinyl)cyclohexane carboxamide trihydrochloride] WAY-100635 (0.3-3 mg/kg) enhanced PA retention. 3) The impairment (1 mg/kg) but not the facilitation (0.03 mg/kg) induced by 8-OH-DPAT was fully blocked by NAD-299 (0.3 mg/kg). 4) 5-HT_1A receptor ligands given immediate post-training failed to alter PA retention. 5) NAD-299 (0.3-1 mg/kg) blocked the impairment of PA retention caused by a) the nonselective muscarinic receptor antagonist scopolamine and b) the non-competitive N-methyl-D-aspartate receptor antagonist MK-801 [(5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5,10-imine hydrogen maleate]. 6) A subthreshold dose of scopolamine completely blocked the facilitatory effect of NAD-299 on PA retention. 7) Anxiety-related behaviors and autonomic function were unchanged by NAD-299. 8) In situ hybridization showed that septal neurons expressing 5-HT_1A receptor mRNA were codistributed with markers for cholinergic, GABAergic, and glutamatergic neurons. These results indicate that systemic administration of 5-HT_1A receptor antagonists can facilitate cognitive performance, most likely by enhancing hippocampal/cortical cholinergic and glutamatergic neurotransmissions. Selective 5-HT_1A receptor antagonists may be useful in the treatment of cognitive deficits such as Alzheimer's disease.

Address correspondence to: Dr. Sven Ove Ögren, Dept of Neuroscience, Div of Behavioral Neuroscience, Karolinska Institutet, Retzius väg 8, SE-171 77 Stockholm, Sweden. E-mail: sven.ove.ogren{at}neuro.ki.se

This article has been cited by other articles:

				W. D. Hirst, T. H. Andree, S. Aschmies, W. E. Childers, T. A. Comery, L. A. Dawson, M. Day, I. B. Feingold, S. M. Grauer, B. L. Harrison, et al. Correlating Efficacy in Rodent Cognition Models with in Vivo 5-Hydroxytryptamine1A Receptor Occupancy by a Novel Antagonist, (R)-N-(2-Methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane Carboxamide (WAY-101405) J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 134 - 145. [Abstract] [Full Text] [PDF]